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Renal amyloidosis is one of the most severe complications of familial Mediterranean fever
(FMF). Colchicine has reduced the incidence of this complication, which now only appears
in  untreated, under-treated and resistant patients, but it is usually ineffective in patients
with  advanced amyloidosis. Here we report a patient with FMF and biopsy-proven amyloid-
osis  who presented with nephrotic syndrome despite colchicine treatment. Anakinra (an
interleukin-1  inhibitor) was started and a dramatic complete remission of nephrotic syn-
drome was observed in the following months. Anakinra can be an effective treatment for
FMF  patients with severe secondary amyloidosis.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Anakinra  induce  la  remisión  completa  del  síndrome  nefrótico  en  un
paciente  con  ﬁebre  mediterránea  familiar  y  amiloidosis
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La amiloidosis renal es una de las complicaciones más graves de la ﬁebre mediterránea
iebre mediterránea familar
miloidosis
olchicina
nakinra
familiar (FMF). La colchicina ha reducido la incidencia de esta complicación, que ahora solo
aparece en pacientes no tratados, tratados de manera insuﬁciente o resistentes al fármaco.
No  obstante, la colchicina se ha mostrado poco eﬁcaz en pacientes que inician el tratamiento
cuando la amiloidosis ya está presente. En este trabajo presentamos el caso de un
enfermo con FMF y amiloidosis renal secundaria diagnosticada mediante biopsia renal que
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desarrolló un síndrome nefrótico completo a pesar del tratamiento con colchicina. Por la
mala  evolución del cuadro se decidió iniciar tratamiento con anakinra (un inhibidor de la
interleucina 1). En los meses posteriores a la instauración del fármaco el enfermo pre-
sentó una mejoría progresiva del síndrome nefrótico, hasta alcanzar la remisión completa.
La  función renal permaneció estable. Los inhibidores de la interleucina 1 pueden ser un
tratamiento efectivo de la FMF en pacientes con amiloidosis renal secundaria.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-NDIntroduction
Familial Mediterranean fever (FMF) is a hereditary inﬂamma-
tory disease with an autosomal recessive pattern.1 It is caused
by mutations in the MEFV gene, which codes for the pro-
tein pyrin. The abnormal synthesis of this protein leads to
the dysregulation of various pathways involved in the control
of inﬂammation (such as synthesis of interleukin-1,  activa-
tion of nuclear factor , and apoptosis),2,3 which produces
a sustained inﬂammatory state in patients with the disease.
Clinically, FMF  manifests as recurrent self-limiting episodes
of fever and polyserositis. This maintained inﬂammation can
lead to secondary amyloidosis (AA), which is one of the most
devastating complications of this disease.4,5 Several stud-
ies have demonstrated the effectiveness of colchicine in the
treatment of FMF,  in reducing the frequency and severity of
inﬂammatory episodes in affected patients and preventing the
onset of AA.6,7 However, colchicine is not effective in patients
with clinical manifestations of AA, particularly if there is renal
amyloidosis.8,9 Anakinra, an interleukin-1  inhibitor, has been
shown to be beneﬁcial in the treatment of FMF, reducing the
number of episodes of the disease.10 In this article we describe
the ﬁrst case of a patient with FMF  and nephrotic syndrome
(NS) secondary to AA with complete remission of NS after
starting treatment with anakinra.
Clinical  case
We  present the case of a 76-year-old man  diagnosed in 1995
with FMF,  on the basis of symptoms of recurrent, self-limiting
episodes of abdominal pain and fever. Following this diagno-
sis, he was prescribed treatment with colchicine at a dose of
0.5 mg  every 12 h, and he remained asymptomatic in subse-
quent years. In November 2010, the colchicine was stopped
by his general practitioner, after which the patient started to
experience episodes of polyarthralgia, chest pain, and abdom-
inal pain. In January 2011 the patient was referred to our centre
for investigation. On examination in clinic, the patient was
afebrile, with a blood pressure of 95/71 mmHg  and a heart
rate of 83 beats per minute. The only ﬁnding of note was
mild ankle oedema. Investigations revealed a serum creati-
nine of 1.33 mg/dL, serum albumin of 2.14 g/dL, cholesterol
of 285 mg/dL, and triglycerides of 295 mg/dL. Proteinuria was
6.1 g/day. Urinary sediment showed 15 red blood cells per
ﬁeld. Other investigation parameters, including leukocytes,(http://creativecommons.org/licenses/by-nc-nd/4.0/).
platelets, and haemoglobin, were normal. Mantoux test was
negative.
Given the suspicion that the patient was experiencing new
episodes of FMF, he was restarted on colchicine, and a genetic
study was performed, which showed the M694 V mutation in
the MEFV gene. Due to the presence of NS, a renal biopsy was
performed: on optical microscopy, amorphous deposits were
seen at a glomerular and vascular level. The deposits were
Congo red positive. Electron microscopy revealed the presence
of randomly arranged, unbranched ﬁbrils measuring 8–10 nm,
characteristic of amyloidosis.
After establishing a diagnosis of NS secondary to AA, the
dose of colchicine was increased to 1 mg/12 h, and enalapril
was started to reduce proteinuria. These measures led to
arterial hypotension and a deterioration in renal function,
therefore enalapril was stopped. The NS worsened, requiring
an increased dose of diuretics to control oedema, there-
fore in February 2011 it was decided to start treatment
with anakinra at a dose of 100 mg/day. Proteinuria began
to decrease from the second month of treatment, and the
patient had a partial remission of NS in the ﬁfth month, as
shown in Fig. 1. Complete remission of NS was achieved after
30 months of treatment (proteinuria < 0.5 g/day). At the most
recent follow-up (42 months after starting anakinra), pro-
teinuria was 0.4 g/day, serum creatinine was 1.18 mg/dL, and
serum albumin was 4 g/dL. The clinical progress of the patient
has been good, with no new episodes of FMF.  The patient has
had no adverse effects related to the anakinra treatment.
Discussion
Secondary amyloidosis is a typical complication in patients
with chronic inﬂammatory disorders.11 Familial Mediter-
ranean fever is the classic hereditary inﬂammatory disease,
and AA is one of its most important complications. The use
of colchicine in FMF was increased after the publication of
several studies demonstrating that it could prevent further
episodes of the disease, and therefore reduce the risk of devel-
oping AA.7–9 Until colchicine was established as the ﬁrst line
treatment in patients with FMF,  60% of patients with this
disease developed AA. Currently, thanks to the widespread
use of colchicine, this prevalence has decreased to 7%.7 How-
ever, the effectiveness of colchicine is limited in patients
with established amyloidosis.10 This limited response is par-
ticularly signiﬁcant in patients with amyloidosis with renal
involvement. Colchicine can stabilise or improve the condi-
tion when proteinuria is below the nephrotic range, but a poor
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Fig. 1 – Patient progress after starting treatment with anakinra. SAlb, serum albumin (g/dL); SCr, serum creatinine (mg/dL);
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esponse has been described in patients with established NS
proteinuria > 3.5 g/day and albumin < 3 g/dL).9–11 In addition,
ome patients are intolerant (2–3%) or resistant (5–10%) to
olchicine.12 In these patients, and in those with advanced
A, the therapeutic options are limited.13 As mentioned in the
ntroduction, mutations in the gene coding for pyrin leads to
n inappropriate activation of interleukin-1,  which seems to
e key in the pathogenesis of FMF.3 This discovery means that
nterleukin-1 inhibitors are a therapeutic option in patients
ith this disease.10,12
In the literature, 30 cases have been described of patients
ith FMF  treated with anakinra. In 20 of them, there were
o ﬁndings of AA, and treatment with anakinra was started
ecause of a persistent inﬂammatory activity not controlled
ith colchicine.10,13–21 In the other 10 cases, renal amyloidosis
as demonstrated. Of those 10 patients, 6 were on a long-term
ialysis programme22–25 and 2 had received a transplant26,27
t the time of starting anakinra. These 8 patients were pre-
cribed anakinra for the control of FMF  inﬂammatory attacks.
nly 2 patients23,28 were treated with anakinra with the aim of
ontrolling glomerular proteinuria secondary to AA, and nei-
her of these cases were in the nephrotic range. Both cases
ad a good clinical outcome, with renal function and pro-
einuria remaining stable after starting anakinra. In the 30
ases described, anakinra reduced or stopped inﬂammatory
pisodes, and very few adverse events were reported.
This is the ﬁrst case described in the literature showing
omplete remission of NS secondary to amyloidosis secondary
o FMF  following treatment with anakinra. Starting anakinra
revented further episodes of the disease, and a progressive
ecrease in proteinuria, remaining below 0.5 g/day from 30
onths (complete remission). Renal function also remained
table. Although a follow-up renal biopsy would have beenvery needed to corroborate a reduction in amyloid deposit in
the kidney, given the good clinical progress in this patient, it
was decided not to perform this procedure. Anakinra may be
a safe, effective, therapeutic alternative in patients with AA
secondary to FMF with signiﬁcant renal involvement; without
treatment, these patients would probably progress to end-
stage renal failure. It is likely that early treatment could lead to
better outcomes. However, the cost of the drug and its possible
adverse effects (increased infections, particularly respiratory
and tuberculosis, and neutropenia)29 should inﬂuence appro-
priate patient selection before starting treatment is essential.
More clinical information is needed to conﬁrm our ﬁndings.
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